Dr. Loutjie Coetzee is the MetOptima Product Manager at Draslovka, and is based in South Africa.
Loutjie has over 16 years of experience in the minerals processing industry, specializing in advanced process control.
He holds a PhD in Electronic Engineering from The University of Pretoria where he completed his doctoral thesis on predictive control of closed run-of-mine ore milling circuits. Loutjie spent several years at Mintek and served as a guest lecturer at The University of Pretoria before joining Draslovka in 2024.
Education
• Business Management Saarland University, Saarbrücken
Professional experience
• 1997 – 2000
MLP AG – Financial Consultant
• 2000 – 2007
Daimler Financial Services AG – Various functions with time abroad (2001 – 2007) in
the USA at the Companies Daimler Truck Financial and Chrysler Financial
• 2007 – 2009
Mercedes Benz AG in Stuttgart, Director for Private and Corporate Business
• 2009 – 2012
Mercedes Benz AG in Stuttgart, Member of the Board for Private and Corporate
Business
• 2012 – 2017
Managing Director at Volkswagen Bank GmbH in Braunschweig
• 2017 – 2019
Managing Director at Volkswagen Leasing GmbH in Braunschweig
• 2019 – 2021
CEO & President VW Credit Inc. in USA
• from 1st October 2021 – CSO Volkswagen Financial Services in Braunschweig
Daniel is an internationally recognised keynote speaker, evangelist and spokesperson, with published articles in the area of cybersecurity, privacy, and reducing your risk on security investments. Daniel has led many teams to success at Kaspersky, McAfee, and IBM.
Jamie Gamerman is the Head of Regulatory Policy at UCB. Prior to UCB, she worked at the FDA for more than a decade, most recently as a Senior Policy Advisor in the Office of Medical Policy within the Center for Drug Evaluation and Research. At the FDA, Jamie was responsible for leading multidisciplinary workgroups to develop guidance documents and regulations. Jamie earned her bachelor’s degree and her law degree from the University of Maryland.
CAPTAIN Mathilda Fienkeng, PharmD, MS, serves as the Director of the Division of Medical Policy Development, in the Center of Drug Evaluation and Research’s Office of Medical Policy at the Food and Drug Administration. In this role, CAPT Fienkeng provides leadership, oversight, and direction to a diverse staff of medical, pharmacy, public health, legal, project management and administrative professionals in the development of new and ongoing policy initiatives pertaining to human drug development, human drug approval, bioresearch monitoring, and human subject protection. She joined FDA in 2008 and has public health experience in prescription drug advertising and promotional labeling review, surveillance and enforcement, drug shortage, and domestic and international emergency response. Prior, she worked as a registered nurse and a Secondary Education Teacher. CAPT Fienkeng was commissioned in the U.S. Public Health Service in 2008 and holds the rank of Captain (O-6). She earned a Doctor of Pharmacy degree and a Master of Science in Regulatory Science from the University of Maryland School of Pharmacy, an executive certificate in Public Policy from Harvard Kennedy School of Executive Education, an Associate of Science in Nursing from Essex Community College, Baltimore MD, and a Bachelor of Arts in Bilingual Education from Ecole Normale Supérieure, University of Yaoundé I, Cameroon.
Dr. Paul Grint is the Executive Chairman of Codagenix. He was most recently CEO and a member of the board of directors of AmpliPhi Biosciences, which merged with C3J Therapeutics to form Armata Pharmaceuticals. Dr. Grint has more than two decades of experience in biologics and small-molecule research and development, including the successful approval and commercialization of products in the infectious diseases, immunology, and oncology therapeutic areas. Dr. Grint has also served in senior management roles at Cerexa, Forest Laboratories, Pfizer, IDEC Pharmaceuticals, and Schering-Plough Corporation. He is currently a board member at Codagenix, Inhibikase Therapeutics, Persephone Biosciences, CRISP QC and Synedgen. He is a Fellow of the Royal College of Pathologists, a member of numerous professional and medical societies, and holds a bachelor’s degree from St. Mary’s Hospital College, University of London and a medical degree from St. Bartholomew’s Hospital College, University of London.
Kay Olmstead co-founded a non-profit organization CARER Group which stands for Catalyzing Access to Research and Equity in Representation. The mission of CARER group is health equity for everyone, and one of their main projects is to promote clinical trial diversity.
Kay is also a founder and CEO of Nano PharmaSolutions. Dr. Olmstead has over 31 years of experience in pharmaceutical industry with drugs approved by FDA and one in Europe.
Dr. Olmstead has published more than 12 manuscripts and has 11 issued patents and 3 pending patent applications. Dr. Olmstead received Ph.D. degree in Organic Chemistry at Johns Hopkins University followed by a NIH post-doctoral fellowship at Stanford University.
